Statins and cancer risk: a meta-analysis

Area of Science:

• Cardiovascular Medicine
• Oncology
• Pharmacology

Background:

• Statins are widely prescribed cholesterol-lowering drugs with established benefits in preventing cardiac events.
• Emerging evidence from retrospective studies suggested a potential role for statins in cancer prevention.

Purpose of the Study:

• To systematically evaluate the impact of statin therapy on cancer incidence and mortality.
• To analyze the effects of statins on specific cancer types and different statin formulations (lipophilic vs. hydrophilic, natural vs. synthetic).

Main Methods:

• A comprehensive literature search was conducted across multiple databases (MEDLINE, EMBASE, etc.) up to July 2005.
• Data from 26 randomized controlled trials (RCTs) involving 86,936 participants were included, focusing on cancer incidence and death.
• Meta-analyses were performed using random-effects models to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Main Results:

• Meta-analyses of 6662 incident cancers and 2407 cancer deaths revealed no significant reduction in cancer incidence (OR, 1.02; 95% CI, 0.97-1.07) or cancer mortality (OR, 1.01; 95% CI, 0.93-1.09) with statin use.
• No specific cancer type showed a reduced incidence or mortality.
• This neutral effect was consistent across hydrophilic, lipophilic, naturally derived, and synthetically derived statins.

Conclusions:

• Randomized controlled trials indicate that statins have a neutral effect on the risk of developing cancer and cancer-related death.
• Statin therapy does not appear to influence the incidence or mortality of any specific cancer type.
• Different subtypes of statins also demonstrated no impact on cancer risk.